Abstract
Introduction
There are currently millions of women diagnosed with breast cancer, who are going through a phase termed the menopause transition, in which there is an increased susceptibility to cardiovascular events 1 . Coronary heart disease (CHD) and cerebrovascular disease are the main cardiovascular diseases. Cardiovascular disease (CVD) is the leading cause of death in women worldwide, competing with breast cancer as the primary cause of death in breast cancer survivors (BCS) 2 . Dyslipidemia, obesity, age, smoking, sedentary lifestyle, hypertension and diabetes mellitus are known risk factors for CVD 1 . Previous studies have identified the high prevalence of CVD risk factors in middle-aged women 3, 4 . Elevated serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) were described in perimenopausal women 5, 6 . The behavior of high-density lipoprotein cholesterol (HDL-C) levels in the menopause transition is less clear and reports have described that HDL-C concentration is not correlated with menopause status 6 . At midlife, BCS may present the same risk factors for CVD as women without breast cancer. As a result, BCS may develop CHD. A higher measurement of TC, LDL-C and TG was reported in BCS, when compared to non-BCS 7, 8 . Furthermore, a relationship between obesity and unfavorable lipid profilehas been demonstrated in BCS 8, 9 . Correlations between obesity [10] [11] [12] , higher blood pressure and lipid levels 11 with worse survival rates in BCS were observed. The addition of traditional risk factors for CVD to chemotherapy [13] [14] [15] , radiotherapy 14 , targeted therapy 16 and endocrine therapy 17 may increase CVD risk in BCS. Use of endocrine therapy may be associated with favorable or unfavorable alterations in lipid profile 17, 18 . CVD risk may be assessed by algorithms or mathematical models. Among the cardiovascular risk assessment models, the Framingham Risk Score (FRS) 19 and the Systematic COronary Risk Evaluation (SCORE) 20 are highlighted. The FRS, developed in the United States, is the most widely used algorithm worldwide 19 for calculation of CHD risk 19 . On the other hand, European guidelines recommend the application of the SCORE system, developed and validated in European countries 20 . The SCORE system estimates the risk of fatal CVD 20 . The prognostic performance of CVD risk assessment models may vary according to the population studied 21, 22 and the clinical condition of the patients 23, 24 . Therefore, the aim of the present study was to investigate the prevalence of CVD risk factors, estimate cardiovascular risk according to the FRS and SCORE model, and evaluate the agreement between these two cardiovascular risk estimation models in middle-aged BCS.
Methods

Patients
Participant selection has been previously described in detail 25 . Briefly, the current sample originated from the Brazilian Breast Cancer and Menopause (BBCAM) study. BBCAM study had a cross-sectional design and was conducted to investigate the prevalence of menopause symptoms, sexual activity, quality of life, bone mineral density and CVD risk in middle-aged BCS 25 .We focused on the cardiovascular risk factors found in this study.
Participants of this study were selected among patients consecutively treated in the Menopause and Breast Cancer Outpatient Facilities in the Women's Hospital, located at the Universidade Estadual de Campinas, Brazil, between August 2002 and June 2003. During outpatient consultation, patients who met the inclusion criteria were invited to participate in the study. BCS, aged 45-65 years, who had not received menopause hormone therapy, tamoxifen or aromatase inhibitors in the last 6 months, and had no history of other malignant tumors were included in the study. Women were invited to participate regardless of menopause status. One hundred BCS were consecutively invited to participate in the study. Three patients refused due to lack of time. Twenty-two patients were undergoing oncology treatment and eight had no record of lipid profile. Sixty-seven BCS comprised the present study sample.
Participants provided information on their sociodemographic characteristics, including age, race/ ethnicity, and marital status. Clinical characteristics included body mass index (weight in kg/height in m 2 ), smoking status, diabetes mellitus, blood pressure levels, time since breast cancer diagnosis, tumor stage, chemotherapy, and radiotherapy. Overweight and obese patients were defined asthose having a body mass index (BMI) between 25.0-29.9 kg/m 2 and ≥30 kg/m 2 , respectively. Blood pressure was measured after rest. Hypertension was defined as a self-reported and/or blood pressure measurement ≥140 and/or ≥90 mmHg. Diabetes mellitus was defined as a self-reported medical diagnosis. The study was approved by the internal review board of the institution. All women signed an informed consent term.
The mean age of the participants was 53.2±6.0 years and mean time since breast cancer diagnosis was 67.7±55.0 months. The mean BMI was 27.8±5.7 kg/m 2 . Seventy percent of the participants reported having one partner, 73% were white, and 84% were postmenopausal. Seventytwo per cent of the participants underwent chemotherapy, and 72% received radiotherapy. Other characteristics of the participants are shown in Table 1 .
Lipid profile
After a 12 hour-fast, blood samples were collected for analysis of serum TC, HDL-C and TG levels. Plasma levels of TC, HDL-C and TG were measured by an enzymatic colorimetric method (Roche Modular system, Roche Diagnostics, Indianapolis, IN), using the Hitachi Modular Analytics system (Roche Diagnostics, Mannheim, Germany). Non-high density lipoprotein cholesterol (non-HDL-C) values were obtained by subtracting HDL-C from TC values 26 . LDL-C concentration was calculated with the Friedewald formula. TC/HDL-C, LDL-C/HDL-C and TG/HDL-C ratios were calculated by dividing TC, LDL-C and TG by HDL-C, respectively.
Dyslipidemia was classified according to the National Cholesterol Education ProgramAdult Treatment Panel III (NCEP-ATP III) guidelines 26 , which considered the following levels elevated: TC ≥200 mg/dL, LDL-C ≥130 mg/dL, TG ≥150 mg/dL and non-HDL-C ≥160 mg/dL. HDL-C values<50 mg/dL were considered low. Ratios were considered high when the following values were observed: TC/ HDL-C >4.5, LDL-C/HDL-C >3.0 and TG/HDL-C >4.0.
Cardiovascular risk assessment
The FRS was validated in a cohort of 5,345 US adults (2,856 women and 2,489 men), aged between 30 and 74 years, followed for12 years 19 . The FRS was developed to assess the relative importance of CHD risk factors and measure the absolute risk of CHD in each patient. The variables used to calculate the FRS were age, gender, smoking status, blood pressure levels, diabetes and values of TC and HDL-C. The10-year CHD riskis classified as low (<10%), moderate (10-20%) and high (>20%) 19 . The SCORE project assembled a pool of datasets from 12 European cohort studies, including 205,178 people (88,080 women and 117,098 men), aged between 45 and 64 years 20 . The SCORE project estimated the total 10-year risk of developing fatal CVD based on age, gender, systolic blood pressure, smoking status and TC level or TC/HDL-C ratio. There are versions for lowand high-risk regions. The 10-year risk of fatal CVD is classified as low (<3%), moderate (≥3 and <5%) and high (≥5%) 20 .
Statistical analysis
Results were presented as means and standard deviations (SD) or as absolute and relative frequencies, according to the type of variable. The prevalence of CVD risk factors was calculated. The kappa coefficient was used to measure the degree of agreement between cardiovascular risk estimated by the Framingham and SCORE risk assessment models. The kappa coefficient and its respective 95% confidence interval (CI) were estimated using SAS software.
Results
The prevalence of overweight, obese and hypertensive patients was 43, 25 and 34%, respectively. The overall prevalence of dyslipidemic patients was 90%. The most common lipid disorders were high TC (70%), high LDL-C (51%) and high non-HDL-C (48%). The prevalence of high non-HDL-C in BCS with TG ≥200 mg/dL was 3%. The prevalence of other CVD risk factors is shown in Table 2 .
Based on the FRS, 22% of BCS had a high10-year risk for CHD. According to the SCORE model, 100 and 93% of BCS had a low10-year risk of fatal CVD, considering populations at low and high risk for CVD, respectively. Considering Brazilian BCS as population at low or high risk for CVD, none of the participants were classified as high risk by the SCORE system (Table 3) .
Considering populations at high risk for CVD, 30 BCS were classified as having a low 10-year risk of CVD and 4 BCS were classified as having a moderate 10-year risk of CVD by both cardiovascular risk models. Agreement between the FRS and SCORE system was poor (kappa: 0.1; 95%CI 0.01-0.2).
Based on the SCORE system, none of the participants had a moderate or high10-year risk of developing fatal CVD, considering populations at low risk for this condition. Thus, a kappa coefficient could not be obtained for populations at low risk for CVD. 
Discussion
The prevalence of CVD risk factors in our study participants was high, with 68% of these women being overweight or obese, slightly higher than the 56% of BCS previously reported to be overweight or obese 9 . Moreover, the prevalence of metabolic syndrome among 158 postmenopausal Brazilian BCS was found to be 48.1% 27 . Abdominal fat was the most frequent diagnostic criterion of metabolic syndrome in BCS, occurring in 54.4% of participants 27 . BCS may gain weight after diagnosis and treatment 10, 27 , with each 5 kg weight gain associated with a 12% increase in all-cause mortality, a 13% increase in breast cancer-specific mortality and a 19% increase in mortality from CVD 10 . Furthermore, obesity may be associated with hypertension. High blood pressure was common in our sample, affecting 34% of BCS. In a study of 494 BCS, the most common comorbid condition was hypertension, with a rate of 19% 9 . Other studies reported hypertension in 26 14 and 50.6% 27 of BCS. In the Shanghai Breast Cancer Survival (SBCS) study, hypertension was the most common comorbid condition, affecting 22.4% of the participants 28 . In the Life after Cancer Epidemiology (LACE) study, hypertension was independently associated with an increased risk of all-cause mortality, due to causes both related and unrelated to breast cancer 29 . This association disappeared, however, after adjusting for antihypertensive medication 29 . The prevalence of hypertension in our sample and in other studies is of concern, indicating the need to control blood pressure to minimize the deleterious effects of hypertension.
Another CVD risk factor was diabetes mellitus, reported by 10% of the participants. Similarly, other studies have reported diabetes mellitus in 6.2 28 , 8 11 and 9% 14 of BCS. In the SBCS study, diabetes was associated with a 40% higher risk of total mortality and death unrelated to breast cancer, but not breast cancer-specific mortality 28 . In another study of BCS, diabetes was associated with a 39% increased risk of all-cause mortality, similar to rates observed in diabetics without breast cancer 30 . These data indicate an association between diabetes and poorer outcomes in breast cancer patients. A worse prognosis in BCS may be due to diabetes-related complications, such as insulin resistance and/or hyperinsulinemia 30 . Dyslipidemia, which may be associated with obesity, hypertension and diabetes 8, 9 , was detected in 90% of our study participants. The prevalence of dyslipidemia in middle-aged women without breast cancer was shown to be 71.5% in Chile 3 and 63.4% in Iran 4 . The most common lipid disorders were high TC, LDL-C and non-HDL-C concentrations. LDL-C is a major cause of CHD, as well as the primary target of lipid-lowering therapy 26 . BMI has been found to be related to TC 8, 9 and LDL-C 8 concentrations in BCS, similar to findings in non-BCS 6 . A study of 104 Brazilian postmenopausal BCS found that the rates of high TC and high LDL-C were 56.7 and 83.4%, respectively 31 . Moreover, a prospective study of non-BCS found that the menopause transition was associated with significant increases in TC and TG concentrations 6 . The Study of Women's Health Across the Nation (SWAN) found that TC, LDL-C and TG levels peaked during late perimenopause and early postmenopause 5 . These findings may explain, at least in part, the prevalence of dyslipidemia in our study cohort and emphasize the importance of evaluating lipid profiles in middle-aged BCS.
The numbers of BCS in this study with high TC/HDL-C, LDL-C/HDL-C and TG/HDL-C ratios were not negligible. LDL-C/HDL-C ratio was shown to increase following menopause 32 , whereas TG/HDL-C 33 and TC/HDL-C 6,32 ratios were found to increase during the menopause transition and postmenopausal periods, two phases the BBCAM study participants were going through. Considering the predictive capacity of CVD risk ratios, our results merit attention in clinical practice, since a considerable proportion of women in our study cohort BCS had elevated ratios, indicating that these women were at higher risk of CVD. High TC/HDL-C ratio (>4.5) 24 36
High LDL-C/HDL-C ratio (>3.0) 19 28 High triglyceride/HDL-C ratio (>4.0) 18 27 Tobacco smoking, another established CVD risk factor, was reported by 12% of the women in our study cohort. Tobacco smoke may lead to coronary endothelial dysfunction and atherosclerosis, possibly via oxidative stress 34 . Furthermore, cigarette smoking may be associated with increased mortality in BCS 35 . For example, results from the LACE study showed that current smokers were at a twofold increased risk of breast cancer-specific mortality and a fourfold higher risk of death unrelated to breast cancer 35 than never smokers. The mechanism relating smoking to poorer outcomes in BCS is not completely understood.
The combination of smoking and radiotherapy has been found to have a more than additive effect on the risk of myocardial infarction 14 . Radiotherapy was employed to treat 72% of our participants. Radiation-related heart toxicities include diseases of the pericardium and myocardium, coronary artery disease, valvular dysfunction and conduction abnormalities 14, 36 . A population-based case-control study involving 2,168 breast cancer patients found that women irradiated for cancer in the left breast had significantly higher rates of major coronary events (i.e., myocardial infarction, coronary revascularization, or death from ischemic heart disease) than those irradiated for cancer in the right breast 37 . Morphology was similar in patients with radiation-related CHD and spontaneous atherosclerosis 36 .
Other therapeutic modalities commonly used to treat breast cancer patients include chemotherapy, targeted therapy and endocrine therapy. Anthracyclines are the most frequently used chemotherapeutic agents for breast cancer. Anthracycline cardiotoxicity is related to cumulative dose, increasing the risk of cardiomyopathy and congestive heart failure 13 . Chemotherapy-related cardiac ischemia is uncommon. However, associations between 5-fluorouracil use and myocardial ischemia have been reported 15 . Data on the chemotherapy agents used in our patients could not be retrieved. Although the targeted therapy trastuzumab has been associated with an increased risk of heart failure 16 , this agent was not available to treat BCS at the time this study was performed. Endocrine therapy with tamoxifen may reduce TC and LDL-C, while increasing TG levels 18 . A systematic review found that the use of aromatase inhibitors, compared with tamoxifen, was associated with increased odds of developing CVD and hypercholesterolemia 17 . BCS have multiple risk factors for CVD, including both traditional and treatment-related factors. Despite the elevated prevalence of risk factors, none of the participants was categorized using the SCORE model as being at highrisk of CVD, whereas 22% were found to be at highrisk according to the FRS model. FRS and SCORE models may overestimate or underestimate CVD risk in different scenarios 21, 22 . A recent systematic review evaluating the use and validity of CVD risk prediction models in Latin America and the Caribbean and among Hispanic populations in the United States reported that FRS overestimates CVD risk among Hispanics when not adequately recalibrated 22 . We found that the agreement between the two risk models was poor. Although no previous studies evaluated the FRS and SCORE risk models in middle-aged BCS, similar results have been reported in other settings 23, 24 . For example, the agreement between FRS and SCORE models in poor Spanish middleaged women 23 and in HIV-positive Brazilian patients 24 . This study had several limitations, including its crosssectional design and relatively small sample size. To our knowledge, this is the first study from Latin America to evaluate the agreement between two CVD risk models in BCS. Routine follow-up of BCS should include lipid profiles and CVD risk assessment.
